The place of dydrogesterone in the treatment of endometriosis and adenomyosis

Karl-Werner Schweppe
Maturitas · 2009 · vol. 65 , pp. S23–S27 · doi:10.1016/j.maturitas.2009.11.011 · PMID:19945806 · W1964654662
article OA: closed CC0 ⤵ 34 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper reviews the role of dydrogesterone in treating endometriosis and adenomyosis, examining its efficacy and safety profile for these gynecological conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Oral progestins have been reported to be effective in the treatment of endometriosis. The mode of action is still a matter of debate, but it may involve modulation of mitotic activity, local growth factors and growth factor receptors, as well as other paracrine mechanisms and anti-inflammatory reactions. Other treatments such as danazol and GnRH-agonists are effective with regard to relief of symptoms and regression of the endometriotic implants, but are associated with high recurrence rates and a wide range of side effects. Progestins are therefore indicated in the symptomatic management of pain, bleeding disorders and other symptoms caused by endometriosis when long-term medication or repeated courses of treatment are indicated. The relationship between costs and efficacy is good, and the side effects are tolerable in most cases. Dydrogesterone is particularly suitable in cases where the woman desires to become pregnant and to prevent bleeding problems. Only very limited data are available concerning the use of progestins in adenomyosis and no conclusions can be drawn.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Dydrogesterone Endometriosis Progestins Dydrogesterone Endometriosis Endometriosis Female Humans Pregnancy Progestins Uterine Hemorrhage Uterine Hemorrhage Uterine Hemorrhage

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (53)

Cited by (34)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:53.633898+00:00
unpaywall
last seen: 2026-07-27T06:55:32.580041+00:00
License: CC0 · commercial use OK